OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Blad... ( BOTHELL WA and VANCOUVER Aug. 13 / On...)

OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer

Date:8/13/2009

BOTHELL, WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1 trial of OGX-427 administered systemically in patients with various solid tumors. OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways.

The study, which will enroll up to 36 patients with bladder cancer, is designed to determine the safety and potential benefit of OGX-427 administered directly into the bladder using a catheter, which is called intravesical instillation. In addition, the study will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells as well as determine the pharmacokinetics and pharmacodynamics of OGX-427 when delivered by intravesical instillation. The study is sponsored by the National Cancer Institute of Canada (NCIC). Dr. Alan So, an Assistant Professor in the Department of Urologic Sciences at the University of British Columbia and Research Scientist at the Vancouver Prostate Centre, is the study's principal investigator.

"The current treatment for superficial bladder cancer is local resection with immunotherapy, which often has significant local and systemic side effects," said Dr. So. "Because of the limitations of current adjuvant options, a treatment option like intravesical delivery of OGX-427 that is specifically targeted to the tumor would be desirable."

"This Phase 1 trial of OGX-427 is an attractive trial design as removal of bladder tumor
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center

Post Your Comments:

(Date:12/14/2009)... Dec. 14 According to Millennium Research ... market intelligence, increased use of safety devices for ... be a key driver of the enteral feeding ... MRG,s new US and European Markets for ... the giving set segment will experience the greatest ...

(Date:12/14/2009)... 14 Mylan Inc. (Nasdaq: MYL ... added to the NASDAQ-100 Index Dec. 21. Mylan,s ... PowerShares QQQ. ,, Mylan Chairman and CEO Robert ... join NASDAQ,s most widely followed index of leading ... for Mylan and reflects the rapid growth and ...

(Date:12/14/2009)... -- Pf enex Inc. announced today ... an affiliate, an exclusive worldwide license to Pf ... technology for the production of specific proteins ... vaccine candidate. ,, Under the terms of the ... $52 million in upfront and milestone payments as well ...

Breaking Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2 Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3 Mylan Added to NASDAQ-100 Index 2 Altcharge com Announces New Services in the Processing Industry 61099 1 Altcharge com Announces New Services in the Processing Industry 61099 2 Particle Sciences Acquires Additional Space for Operations 14790 1 Particle Sciences Acquires Additional Space for Operations 14790 2 Amedica Announces New Product Offering 14788 1 Amedica Announces New Product Offering 14788 2

[0] Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 [0] Mylan Added to NASDAQ-100 Index [0] Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program

... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported today ... that its EnviroTru(R),disinfectant has been assigned a commodity ... the State of Florida. The Company reported,that its ... http://www.aworldofgreen.com ),worked with the DMS to have ...

... An overwhelming number of,Americans with memory concerns ... despite visits within the past six months, according ... in the Alzheimer,s Foundation of,America (AFA) National Memory ... results at a poster session at the Alzheimer,s,Association,s ...

Other Medicine Technology:Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2 Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3 Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2 Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3

Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors

(Date:12/15/2009)... Oakworks ® Inc. America,s premier manufacturer of Spa, Massage, and ... the development of an adjustable breast comfort system to ease ... ... New Freedom, Pennsylvania (PRWEB) December 15, ... massage, and medical equipment, today announced the launch of the ...

(Date:12/15/2009)... and Telangiectasia , ... (PRWEB) December 10, 2009 -- Millions of men ... – those unsightly clusters of red, blue or purple veins that spider-web ... populations like the US, it’s been estimated that 25-30% of women and ... , ,Although the Veinwave has been available for over 8 ...

(Date:12/15/2009)... SAN DIEGO, Dec. 15 "The entire San ... mourns the passing of Sol Price on December 14, ... standards of integrity, loyalty and ethics in his business, ... and thoughtful humanitarian who truly understood the responsibility of ... and his legacy will live on through his countless ...

(Date:12/15/2009)... Westchester, Ill. A study in the Dec. ... Sleep Medicine indicates that significant associations exist ... gastrointestinal regurgitation and headaches in young school-aged children. ... that parent-reported insomnia was 3.3 times more likely ... more likely in children with headaches. Nineteen ...

(Date:12/14/2009)... Unmarried Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, ... Nearly all unmarried young adults ages 18-29 ... of men and 86% of women) and say that ... right now (86% of men and 88% of women), ... to Prevent Teen and Unplanned Pregnancy. Even so: ...

Breaking Medicine News(10 mins):Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4 Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2 Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2 Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2 Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3

[0] Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table [0] Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device [1] San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price [1] Insomnia symptoms linked with medical complaints in young school-aged children [1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference

... Grand Prize winner Judy McAtee of Plato Center, IL for, her dedication ... for their acts of caring; CVS/pharmacy employee, winner honored for kidney ... ... NEW YORK, March 3 Today CVS/pharmacy announced the,Grand Prize winner ...

... The world market for catheters was,valued at more than ... more,than 60% in the next five years. The cardiovascular ... catheter market in terms of value,and will witness the ... angioplasty demonstrating the greatest increase,according to Kalorama Information,s new ...

... STEVENSVILLE, Md., March 3 Vapotherm, the,global leader ... that,its President & CEO, Robert Storey earned Maryland,s ... Center Institute (WTCI).,Storey was one of seven winners ... and creative strategy in international,business. The award will ...

... nano-sensor for better detection of Mad Cow Disease agent, ... food safety, researchers in New York are reporting development ... of the deadly prion proteins that cause Mad Cow ... detects binding of prion proteins by detecting frequency changes ...

... off risky behaviors, study suggests , , MONDAY, March 3 (HealthDay ... new research suggests it,s not a good idea to just ... Instead, the study recommends that you encourage an ongoing dialogue ... you uncomfortable -- so your kids are less likely to ...

... 3 AT&T Inc. (NYSE: T ),announced ... system,to provide voice coverage and mobile broadband access ... (Jefferson)., "Jefferson is committed to excellence in ... Jefferson University,Hospital. "Since communication at every level is ...

Caregivers are Honored as CVS/pharmacy Announces Winners of the 'For All the Ways You Care' Contest Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales Vapotherm CEO Receives Top Business Leadership Award From World Trade Center Institute American Chemical Society's weekly PressPac -- Feb. 27, 2008 That 'Sex Talk' With Your Kids Should Be Ongoing AT&T Provides In-Building Wireless Services to Thomas Jefferson University and Hospital

... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...

... and specific second-generation peptide-based test, DIASTAT Anti-CCP* ... of autoantibodies against the cyclic citrullinated peptide ... serum or plasma. Enabling early and accurate ... an additional tool in the diagnosis and ...

... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...

Hemagglutination slide test for the qualitative detection and quantitative determination of antibodies to streptococcal extracellular antigens in serum, plasma, or whole blood....

Medicine Products:

Scl-70 II ELISA Kit DIASTAT™ Anti-CCP Wampole Impact Syphilis RPR® Test Kit Streptozyme® Streptococcal Antibody Test

OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Blad...( BOTHELL WA and VANCOUVER Aug. 13 / On...),Health